Perth biomedical firm Orthocell has gained a toehold in China for its nerve repair product via a deal with a Hong Kong-based medical products distributor.
Orthocell has entered an MOU to secure exclusive distribution rights for Marine Biomedical's innovative bone substitute PearlBone, and lift its stake in the company to 12 per cent.
WA biotech Orthocell has announced a promising new use case for its Remplir nerve regeneration product, this time in reducing post-surgical complications in prostate cancer sufferers.
A day after announcing a record quarterly revenue of $2.7 million, Perth medtech Orthocell has appointed a former Pilbara Minerals figure and ex-Olympian to its executive team.
Murdoch-based Orthocell's push to expand the reach of its nerve repair product Remplir has continued, following news it has received regulatory approval in Hong Kong.
Orthocell boss Paul Anderson said the Murdoch-based biotech medical company is “well ahead” of its original targets in relation to US sales of its nerve repair product, Remplir.
Shares in Murdoch-based Orthocell rose by 15 per cent early on Wednesday, following news the biotech medical company had received regulatory approval to sell its nerve repair product in Canada.
Fresh from receiving clearance from the Food and Drug Administration to distribute its nerve repair product Remplir in the US earlier this month, Murdoch-based Orthocell has appointed an initial four distributors.
Orthocell has posted its fourth consecutive quarter of record revenue, as the regenerative medicine company continues to expand its reach around the globe.
Singapore's Health Science Authority has granted regulatory approval for John Van Der Wielen-chaired Orthocell for use of its dental membrane project, Striate+.
Kim Beazley-backed medtech company Orthocell has flagged an expedited expansion into several jurisdictions after strong early sales of its Remplir nerve repair technology.
Murdoch-based regenerative medicine company Orthocell has posted its third consecutive quarter of record revenue, as it gears up for a final approval from the US FDA for its Remplir nerve product.
Orthocell has submitted its application for US Food and Drug Administration approval for its Remplir nerve regeneration product, marking another moment in a year full of milestones.
Biotech firm Orthocell is a step closer to its nerve repair device Remplir being approved in the US, following the completion of its US regulatory study.
Orthocell has struck a deal with a medical equipment supply firm to distribute its nerve repair device in Singapore, sending the Perth company's shares up 26 per cent.
Perth-based biotechnology firm Orthocell has raised $17 million to take its Remplir nerve regeneration product to the world's biggest healthcare market.
Murdoch-based Orthocell has received regulatory approval to commence sales of Remplir in Singapore, as the listed biotech company posts a second consecutive quarter of record revenue.
SPECIAL REPORT: As markets struggle under the pressure of the COVID-19 pandemic, the medtech industry has found itself with an unparalleled, if challenging, opportunity.
Bio-therapeutic company Orthocell has received commitments to raise $13 million from a share placement and up to a further $5 million from a share purchase plan, primarily to accelerate the commercialisation of its CelGro flagship product.
Shares in Perth biotech Orthocell more than quadrupled in value today after the company released positive results from a trial of its nerve regeneration product.
Shares in Perth-based Orthocell have soared after the tissue regeneration company was granted a patent for its "cell factory" technology in the United States.
Shares in Perth-based biotechnology company Orthocell have risen slightly on the back of it striking a partnership with leading Swedish medical technology company Bonesupport.
The recent publication of two listings of influential business leaders provided food for thought about the growing international influence on Western Australia.
